Postoperative recurrence of non-muscle invasive bladder cancer (NMIBC)
Conditions
Interventions
Urine HK2 monitoring cohort:None
Sponsors
The affiliated people's hospital of Ningbo University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with pathologically confirmed Ta, T1, or CIS stage; 2. Those who have undergone transurethral resection of bladder tumor (TURBT) and received routine postoperative intravesical infusion therapy; 3. Patients with complete clinical follow-up data and informed consent to participate in this study; 4. Those with stable postoperative status, no serious postoperative complications, and capable of cooperating with follow-up visits as well as urine/cystoscopy examinations.
Exclusion criteria
Exclusion criteria: 1. Patients with concurrent upper urinary tract tumor, active urinary tract infection, or severe metabolic diseases; 2. Those receiving systemic anti-tumor therapy (including systemic intravenous chemotherapy, targeted therapy, or immune checkpoint inhibitors) or those who have participated in other interventional studies recently that may interfere with the detection of urinary biomarkers; 3. Patients with severe complications involving cardiac, hepatic, or renal insufficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression level of urinary metabolic biomarker HK2 in urothelial cells or exosomes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Area Under the Receiver Operating Characteristic Curve (AUC);Source Mechanism of HK2 in Urinary Shed Cells (Urothelial Cells and Exosomes);Association Analysis between HK2 and Metabolic Reprogramming-Related Genes (e.g., SREBF1, FASN) and Signaling Pathways (PI3K/AKT/mTOR, EGFR/AKT); | — |
Countries
China
Contacts
Public ContactLi Ping
The affiliated people's hospital of Ningbo University
Outcome results
None listed